CASI Pharmaceuticals, Inc. (CASI)
Largest Insider Buys in Sector
CASI Stock Price History Chart
CASI Stock Performance
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and …
Insider Activity of CASI Pharmaceuticals, Inc.
Over the last 12 months, insiders at CASI Pharmaceuticals, Inc. have bought $0 and sold $0 worth of CASI Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at CASI Pharmaceuticals, Inc. have bought $6.57M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 33,300 shares for transaction amount of $142,627 was made by Huang James () on 2022‑09‑06.
List of Insider Buy and Sell Transactions, CASI Pharmaceuticals, Inc.
| 2022-09-06 | 33,300 0.2621% | $4.28 | $142,627 | -44.50% | ||||
| 2022-08-31 | 400 0.0029% | $3.74 | $1,497 | -40.27% | ||||
| 2022-08-24 | 39,527 0.2821% | $3.75 | $148,179 | -41.97% | ||||
| 2022-08-19 | 40,000 0.294% | $3.50 | $139,992 | -36.29% | ||||
| 2022-06-13 | Chairman and CEO | 2,096 0.0157% | $3.06 | $6,414 | -21.59% | |||
| 2021-11-18 | Chairman and CEO | 200,000 0.1522% | $0.98 | $196,000 | -56.84% | |||
| 2021-11-17 | Chairman and CEO | 200,000 0.1484% | $0.99 | $198,000 | -58.11% | |||
| 2021-08-19 | Chairman and CEO | 180,000 0.0132% | $1.26 | $226,800 | -35.37% | |||
| 2021-08-18 | Chairman and CEO | 300,000 0.0213% | $1.29 | $387,000 | -38.46% | |||
| 2021-03-26 | Chairman and CEO | 3M 0.2392% | $2.05 | $6.15M | -42.48% | |||
| 2020-12-17 | Chief Financial Officer | 4,000 0.0003% | $2.63 | $10,537 | -41.82% | |||
| 2020-12-16 | Chief Financial Officer | 2,000 0.0002% | $2.44 | $4,880 | -39.85% | |||
| 2020-11-23 | Chairman and CEO | 100,000 0.0082% | $2.18 | $218,000 | -27.78% | |||
| 2020-11-20 | Chairman and CEO | 127,471 0.0104% | $2.12 | $270,239 | -26.24% | |||
| 2020-07-22 | Chairman and CEO | 4.15M 0.3521% | $1.90 | $7.89M | +1.05% | |||
| 2020-07-22 | President | 20,153 0.0017% | $1.90 | $38,291 | +1.05% | |||
| 2020-05-20 | Chairman and CEO | 56,464 0.0054% | $2.37 | $133,820 | -12.20% | |||
| 2020-05-19 | Chairman and CEO | 29,801 0.0029% | $2.03 | $60,496 | +6.10% | |||
| 2020-05-18 | Chairman and CEO | 338,932 0.0341% | $2.02 | $684,643 | +9.30% | |||
| 2020-05-15 | Chairman and CEO | 100,000 0.0095% | $1.82 | $182,000 | +15.34% |
Insider Historical Profitability
| IDG-Accel China Growth Fund III L.P. | 10 percent owner | 9126375 68.1002% | $2.82 | 2 | 0 | <0.0001% |
| SPARKLE BYTE LTD | 10 percent owner | 8498765 63.417% | $2.82 | 1 | 0 | +3.48% |
| SPECTRUM PHARMACEUTICALS INC | director | 6897413 51.4679% | $2.82 | 5 | 0 | +27.02% |
| He Wei-Wu | Chairman and CEO | 594553 4.4365% | $2.82 | 31 | 0 | +28.31% |
| Huang James | 371517 2.7722% | $2.82 | 4 | 0 | <0.0001% |
Institutional Investor Ownership
| Wellington Shields Capital Management LLC | $332,903.00 | 0.69 | 92,217 | -30.74% | -$147,753.53 | 0.06 | |
| Wellington Shields | $308,532.00 | 0.32 | 43,091 | 0% | +$0 | 0.1 | |
| Howland Capital Management | $145,949.00 | 0.3 | 40,429 | New | +$145,949.00 | 0.01 | |
| Renaissance Technologies | $133,000.00 | 0.28 | 36,800 | +26.46% | +$27,828.80 | <0.0001 | |
| Geode Capital Management | $80,217.00 | 0.17 | 22,221 | 0% | +$0 | <0.0001 |